Retatrutide Phase 3 Data Near as Gray-Market Deaths Expose Peptide Supply Risk
Retatrutide is nearing the end of phase 3 but remains unapproved, while two deaths linked to gray-market versions were reported to the FDA, sharpening supply-chain scrutiny.